Arrowhead describes new RNAi delivery vehicle; FDA delays oral disintegrating tablet for ADHD;

> RNAi specialist Arrowhead discussed new enhancements to the company's RNAi drug delivery platform, including a new proprietary subcutaneous delivery vehicle, at the meeting of the Oligonucleotide Therapeutics Society in the Netherlands. More

> The FDA had identified deficiencies with Neos Therapeutics' extended-release oral disintegrating tablet for ADHD during a review of the candidate's New Drug Application. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.